Lung Adenocarcinoma
Conditions
Keywords
Adenocarcinoma, EGFR, Gefitinib, Pemetrexed, Carboplatin
Brief summary
The purpose of this study is to compare chemotherapy and gefitinib in combination with gefitinib alone as first-line therapy for adenocarcinoma, in terms of efficacy and safety.
Detailed description
The primary endpoints is to compare the progression-free survival (PFS) of pemetrexed plus carboplatin combined with gefitinib to gefitinib alone as first-line therapy for lung adenocarcinoma. In addition, the overall survival and safety index will be collected for analyses.
Interventions
DRUGPemetrexed plus carboplatin combined with gefitinib
Pemetrexed (500mg/m(2) d1) plus carboplatin (AUC5 d1) combined with gefitinib (250mg d4-28) and repeat every four weeks for up to six cycles and then continue to receive pemetrexed combined with gefitinib every four weeks.
DRUGGefitinib
Gefitinib (250mg daily)
Sponsors
Ruijin Hospital
Changhai Hospital
Shanghai Chest Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Patients had to voluntarily join the study and give written informed consent for the study; 2. Histologically documented, unresectable, inoperable, locally advanced, recurrent or metastatic stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC); 3. A cytologic diagnosis is acceptable (FNA or pleural fluid cytology) 4. Sensitive EGFR mutations (19del, 21L858R); 5. At least 1 unidimensionally measurable lesion meeting Response Evaluation Criteria in Solid Tumours (RECIST) criteria; 6. Patients did not receive systemic anti-cancer therapy previously; 7. Able to comply with study and follow-up procedures; 8. Age \>= 18 years, ECOG PS: 0-1, estimated survival duration more than 3 months;
Exclusion criteria
1. Small cell lung cancer (including patients with mixed small cell lung cancer and non-small cell lung cancer); 2. Evidence of small cell, carcinoid, or mixed small cell/non-small cell histology; 3. EGFR wild-type patients, or patients with rare EGFR mutations or complex EGFR mutations; 4. Previously (within 5 years) or presently suffering from other malignancies, except for cured cervical carcinoma in situ, non-melanoma skin cancers and superficial bladder cancer \[Ta (noninvasive carcinoma), Tis (carcinoma in situ) and T1 (invasion into lamina propria)\]; 5. Symptomatic or untreated brain metastases; 6. Unstable systemic disease, including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, or myocardial infarction within 6 months prior to Day 1, or serious cardiac arrhythmia requiring medication (patients with chronic atrial arrhythmia, i.e., atrial fibrillation or paroxysmal supraventricular tachycardia, are eligible); 7. History of other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the patient at high risk from treatment complications; 8. Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous (IV) alimentation, or prior surgical procedures affecting absorption; 9. Pregnancy or lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival (PFS) | 16 months |
Secondary
| Measure | Time frame |
|---|---|
| overall survival (OS) | 32 months |
| Objective response rate (ORR) | 6 months |
| Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 | 6 months |
Contacts
Primary ContactAiqin Gu, MD
Outcome results
None listed